This site contains materials related to Novo Nordisk scientific presentations at the Advanced Technologies & Treatments for Diabetes (ATTD) 2020 congress. The information on this site is intended for Healthcare Providers only and may relate to data concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. The information contained in this site is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product. Furthermore, it is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation.

The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have any questions regarding any information contained on this site you should consult a physician.

Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this website.

I have read and accept the legal notice for Novo Nordisk scientific presentations at ATTD 2020.

 Accept  Decline

13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Madrid, Spain, 19–22 February 2020

Oral Semaglutide

Insulin degludec/insulin aspart

Fast-acting insulin aspart

Devices

Poster book